Background Familial chylomicronemia syndrome is a genetic disorder associated with
severe hypertriglyceridemia and severe acute pancreatitis. Olezarsen reduces the plasma …

Worldwide, the prevalence of obesity and diabetes have increased, with heart disease being
their leading cause of death. Traditionally, the management of obesity and diabetes has …

There is a gap of knowledge about the clinical and pathophysiological implications resulting
from the interaction between primary hyperlipidemias and type 2 diabetes (T2D). Most of the …

Introduction Dyslipidemia plays a crucial role in the development of atherosclerotic
cardiovascular diseases. Areas covered This article explores the emerging therapeutic …

In recent years, novel apoC3 inhibitor therapies for the treatment of hypertriglyceridemia
have been developed and assessed through phase II and III clinical trials. The objective of …

Nucleic acid-based therapies are being rapidly developed for prevention and management
of cardiovascular diseases (CVD). Remarkable advancements have been achieved in the …

ABSTRACT Introduction Apolipoprotein (apo) C-III, a key regulator of plasma triglyceride
(TG) levels, is a prime candidate for the treatment of hypertriglyceridemia (HTG), prevention …

Very-low-density lipoprotein (VLDL), a triglyceride-rich lipoprotein secreted by hepatocytes,
is pivotal for supplying peripheral tissues with fatty acids for energy production. As if walking …

Aims Since its discovery, the patatin‐like phospholipase domain containing 3
(PNPLA3)(rs738409 C> G p. I148M) variant has been studied extensively to unravel its …

Abstract Purpose of Review Multiple agents are being developed that inhibit apolipoprotein
(apo) C-III. This state-of-the-art review examines their potential for atherosclerotic …